We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Abbott Diagnostics- Hematology Division

Download Mobile App

Ultra-Fast, Fully Automated SARS-CoV-2 Virus Detection Test Uniquely Suited for Near Patient Testing

By LabMedica International staff writers
Posted on 28 Jul 2021
Print article
Image: The PCR ONE SARS-CoV-2 panel (Photo courtesy of Curiosity Diagnostics)
Image: The PCR ONE SARS-CoV-2 panel (Photo courtesy of Curiosity Diagnostics)
A fully automated SARS-CoV-2 virus detection test is believed to be one of the fastest tests in the world and is uniquely suited for near patient testing.

Developed by Curiosity Diagnostics (Warsaw, Poland), a wholly-owned subsidiary of Scope Fluidics S.A. (Warsaw, Poland), the PCR|ONE SARS-CoV-2 panel is now CE-marked and can be introduced to the European market. The PCR|ONE SARS-CoV-2 panel uniquely combines several key parameters such as ease of use, affordable cost, very short testing time and informativeness.

Among all the rapid genetic tests for SARS-CoV-2, the PCR|ONE test is the most reliable method of detecting SARS-CoV-2 and also one the fastest on the market. A number of testing locations will benefit from the system’s unique performance, especially where fast and accurate diagnosis is important – from medical centers to any location frequented by the public.

The PCR|ONE system for SARS-CoV-2 virus detection successfully passed in-depth testing in external hospital laboratories, achieving very high values for the most relevant clinical parameters: 91.2% sensitivity and 100% specificity. On the other hand, in the analysis of samples containing higher amounts of viral RNA (samples from patients likely to infect other people), the PCR|ONE system proved flawless, obtaining 100% sensitivity and 100% specificity. PCR|ONE with the SARS-CoV-2 panel was also tested the PCR|ONE system at the Warsaw Chopin Airport, where passengers from almost all over the world arrive.

“PCR|ONE is designed to test for a number of targets in the SARS-CoV-2 genome,” said Vincent Linder, Ph.D., author of more than 300 patents in microfluidic techniques and point-of-care diagnostics, founder of a diagnostics startup at Harvard University, and member of the Scope Fluidics Board of Experts. “As such it can be easily adapted to include new genetic targets to timely address the threat posed by new variants of the virus. It is a system that has an enormous growth potential – as a powerful tool to fight the COVID-19 pandemic and also a number of other conditions where a timely diagnosis allows for rapid initiation of treatment and improvement in patient outcome.”

“We have demonstrated the versatility of the PCR|ONE system. We knew that it could be used to identify bacterial DNA along with checking their antibiotic susceptibility. Now we know that it can also be used to identify virtually any pathogen in the world. This will open way for a very broad application of the PCR|ONE system in medical diagnostics,” said Dr. Kamil Gewartowski, PCR|ONE project manager at Scope Fluidics.

Related Links:
Curiosity Diagnostics
Scope Fluidics S.A.

Gold Supplier
Sample Transport
VACUETTE Transport Line
Direct-to-PCR Workflow for SARS-COV-2 Detection
Direct to PCR SARS-COV-2 Solution
Gold Supplier
SARS-COV-2 PLUS UK Real Time PCR kit
Laboratory Management Software

Print article



view channel
Image: The CellSearch Circulating Tumor Cell Kit is intended for the enumeration of circulating tumor cells of epithelial origin (CD45-, EpCAM+, and cytokeratins 8, 18+, and/or 19+ and PD-L1) in whole blood (Photo courtesy of CellSearch/Menarini Silicon Biosystems)

PD-L1 Expression in Circulating Tumor Cells Investigated for NSCLC

In non-small cell lung cancer (NSCLC), analysis of programmed cell death ligand 1 (PD-L1) expression in circulating tumor cells (CTCs) is a potential alternative to overcome the problems linked to the... Read more


view channel

Global Digital Polymerase Chain Reaction (dPCR) Market Projected to Reach Close to USD 1.15 Billion by 2028

The global digital polymerase chain reaction (dPCR) market is projected to grow at a CAGR of more than 9% from over USD 0.50 billion in 2020 to nearly USD 1.15 billion by 2028, driven primarily by rising... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.